Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
Rasmus Michael Sandsdal, Christian R. Juhl, Simon Birk Kjær Jensen, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

New insights into the treatment of obesity
Matthias Blüher, Mohini Aras, Louis J. Aronne, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 8, pp. 2058-2072
Closed Access | Times Cited: 93
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Saleh Hadi Alharbi
Therapeutic Advances in Endocrinology and Metabolism (2024) Vol. 15
Open Access | Times Cited: 70
Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial
Simon Birk Kjær Jensen, Martin Bæk Blond, Rasmus Michael Sandsdal, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102475-102475
Open Access | Times Cited: 65
Obesity and cardiovascular disease: an ESC clinical consensus statement
Konstantinos C. Koskinas, Emeline M. Van Craenenbroeck, Charalambos Antoniades, et al.
European Heart Journal (2024)
Open Access | Times Cited: 53
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
Clara Luna-Marco, Francesca Iannantuoni, Alberto Hermo-Argibay, et al.
Free Radical Biology and Medicine (2024) Vol. 213, pp. 19-35
Open Access | Times Cited: 28
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
Tong Bu, Ziyan Sun, Yi Pan, et al.
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 3, pp. 354-372
Open Access | Times Cited: 23
Inflammation and resolution in obesity
Matúš Soták, Madison Clark, Bianca E Suur, et al.
Nature Reviews Endocrinology (2024)
Closed Access | Times Cited: 19
Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity
Jeffrey I. Mechanick, W. Scott Butsch, Sandra M. Christensen, et al.
Obesity Reviews (2024)
Open Access | Times Cited: 18
Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
Frederick Berro Rivera, Grace Nooriza O. Lumbang, Danielle Rose Magno Gaid, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2209-2228
Open Access | Times Cited: 16
Obesity and cardiovascular disease: an ESC clinical consensus statement
Konstantinos C. Koskinas, Emeline M. Van Craenenbroeck, Charalambos Antoniades, et al.
European Journal of Preventive Cardiology (2024)
Open Access | Times Cited: 16
Association between Life’s Crucial 9 and overactive bladder: the mediating role of weight-adjusted-waist index
Hongyang Gong, Shuqin Duan, Shaoqun Huang
Frontiers in Nutrition (2025) Vol. 11
Open Access | Times Cited: 2
Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety
Alberte Laura Oest Müllertz, Rasmus Michael Sandsdal, Simon Birk Kjær Jensen, et al.
Obesity Reviews (2024) Vol. 25, Iss. 5
Open Access | Times Cited: 15
Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?
Elena Domingo, Patrice Marqués, Vera Francisco, et al.
Pharmacological Research (2024) Vol. 200, pp. 107058-107058
Open Access | Times Cited: 11
Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
Magda Wojtara, A Mazumder, Yusra Syeda, et al.
Advances in Medicine (2023) Vol. 2023, pp. 1-7
Open Access | Times Cited: 18
Unintended consequences of glucagon-like peptide-1 receptor agonists medications in children and adolescents: A call to action
Dan M. Cooper, Mark A. Rothstein, Alpesh Amin, et al.
Journal of Clinical and Translational Science (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 17
The Role of Inflammatory Mediators in the Pathogenesis of Obesity
Estera Bakinowska, Mariusz Krompiewski, Dominika Boboryko, et al.
Nutrients (2024) Vol. 16, Iss. 17, pp. 2822-2822
Open Access | Times Cited: 8
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis
Paschalis Karakasis, Dimitrios Patoulias, Nikolaos Fragakis, et al.
Metabolism (2024), pp. 156113-156113
Closed Access | Times Cited: 8
Body Fat Distribution, Diabetes Mellitus, and Cardiovascular Disease: an Update
Puneet S. Kang, Ian J. Neeland
Current Cardiology Reports (2023) Vol. 25, Iss. 11, pp. 1555-1564
Closed Access | Times Cited: 14
Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice
Eric M. Desjardins, Jianhan Wu, Declan C. T. Lavoie, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 9, pp. 101193-101193
Open Access | Times Cited: 13
Targeting the Gut Microbiota for Prevention and Management of Type 2 Diabetes
Sabrina Donati Zeppa, Marco Gervasi, Alessia Bartolacci, et al.
Nutrients (2024) Vol. 16, Iss. 22, pp. 3951-3951
Open Access | Times Cited: 4
The assessment of exhaled nitric oxide in patients with obesity and asthma before and after exercise
Burcu Parlak, Zeynep Tamay, Nermin Güler
Journal of Asthma (2025), pp. 1-10
Closed Access
Análise das diferentes respostas ao tratamento com agonistas GLP-1 em diabetes tipo 1 e tipo 2 e a personalização dos tratamentos
G. F. de Carvalho, GUSTAVO PACIFICO MAIA ANTERO DE SOUSA, Gabriel Moraes, et al.
Contribuciones a las Ciencias Sociales (2025) Vol. 18, Iss. 1, pp. e14682-e14682
Closed Access
In vivo medical imaging for assessing geroprotective interventions in humans
Jonas E. Svensson, Martin Schain, Pontus Plavén‐Sigray
GeroScience (2025)
Open Access
Asociación entre las variables sociodemográficas, los hábitos saludables y el estrés con síndrome metabólico: un estudio descriptivo y transversal
Ángel Arturo López‐González, Emilio Martínez-Almoyna Rifá, Hernán Paublini, et al.
Medicina de Familia SEMERGEN (2025) Vol. 51, Iss. 6, pp. 102455-102455
Closed Access
GLP‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
Tommaso Bucci, Uazman Alam, Grégoire Fauchier, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Page 1 - Next Page

Scroll to top